This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2012 Fourth Quarter And Full Year Results

Net research, development and engineering costs (“RD&E”) for the 2012 fourth quarter and full-year of 2012 were $11.2 million and $52.5 million, respectively, compared to $12.8 million and $45.5 million, respectively, for the comparable 2011 periods. For the fourth quarter and full-year of 2012, our acquisitions added $0.2 million and $2.6 million, respectively, to RD&E. RD&E amounts for the fourth quarter of 2012 and 2011 include $1.4 million and $2.3 million, respectively, of design verification testing (“DVT”) costs in connection with our development of a neuromodulation platform. For the year, DVT expenses were $5.2 million for 2012 and $5.1 million for 2011. RD&E for the second half of 2012 was lower than the first half of 2012 by $3.7 million as the Company refocused its medical device R&D investment and discontinued non-core R&D projects. Additionally, the fourth quarter of 2012 included $1.7 million of additional customer cost reimbursements due to the timing of when milestones on certain projects were achieved. For the year, customer cost reimbursements increased $1.4 million in comparison to 2011. Excluding DVT related expenses, medical device adjusted expenses were $28.5 million for 2012 compared to $22.1 million for 2011. Going forward, the Company intends to continue to look for ways to reduce the RD&E investment impact on its bottom line which will include identifying strategic partners to share these costs, monetizing non-core technology assets and refocusing our medical device technology investment towards Algostim and the portable medical markets.

GAAP operating income for the fourth quarter and full-year 2012 was $1.4 million and $25.8 million, respectively, compared to $12.5 million and $61.7 million for the respective periods of 2011. This decrease was primarily due to the charges incurred in connection with the consolidation of our Swiss orthopaedic operations, as well as other productivity initiatives which are expected to ultimately drive improved profitability. Adjusted operating income, which excludes these costs as well as other charges, was $21.1 million and $73.9 million for the 2012 fourth quarter and full-year, respectively, compared to $15.7 million and $67.6 million, respectively, for the comparable 2011 periods. Refer to Table A at the end of this release for a reconciliation of GAAP operating income to adjusted operating income and the “Use of Non-GAAP Financial Information” section below.

4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs